SciELO - Scientific Electronic Library Online

 
vol.8 número1Effectiveness and safety of the use of alpha-keto analogues in the management of advanced chronic kidney disease: clinical practice recommendations índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Colombiana de Nefrología

versão On-line ISSN 2500-5006

Resumo

FORERO DELGADILLO, Jessica et al. IgA nephropathy in pediatric patients, clinical outcomes with three types of management. Rev. colom. nefrol. [online]. 2021, vol.8, n.1, e201.  Epub 22-Out-2021. ISSN 2500-5006.  https://doi.org/10.22265/acnef.8.1.422.

Introduction:

IgA nephropathy (IgAN) is the most common glomerular disease in the world, in Colombia belongs to 11-22 % of primary glomerulonephritis in pediatric patients. Of these, 30 % progress to chronic kidney disease.

Materials and methods

: It is a retrospective descriptive study. We used median and IRQ for continuous variables, and proportions for categorical variables, Fisher test to compare clinical outcomes.

Results:

Between 1996 to 2013 58 patients were diagnosed. The mean age at symptoms onset was 7.5 years (SD±4.2) and at the time of renal biopsy was 10 years (SD±3.8). At diagnosis, 77.6 % of the patients showed microscopic hematuria, 27.6 % gross hematuria and 81 % proteinuria, classified as severe in 29 %. Three patients required dialysis and two needed kidney transplant. Three groups with different therapeutic regimens were evaluated: first group only prednisone 34.5 % (n = 20), second group prednisone and mycophenolate mofetil (MMF) 22.4 % (n = 13) and third group without prednisone neither MMF 43.1 % (n = 25). The difference in the presence of hematuria among the groups was significant (p> 0.001), being more frequent in the group without prednisone neither MMF (68 %). There were no significant differences in proteinuria, hypertension or creatinine among the groups. The median of years between the renal biopsy and the last control was 4 years RI 1-7. At five years, the renal function survival probability (GFR >90 ml/min/1.73m2) was 89.1 %.

Conclusion:

IgAN needs early recognition and strict follow-up, since it may have ominous outcomes.

Palavras-chave : Glomerulonephritis; Immunoglobulin A; children; hematuria; proteinuria; Schoenlein-Henoch purpura; vasculitis..

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )